Davunetide has published research citations on file; FGL does not yet — the main evidence gap between them.
Davunetide
Evidence
FGL
Evidence
| Your goal | Better option |
|---|---|
| Has published research citations | Davunetide |
| Further along in FDA review | Davunetide |
| More provider options (0 vs 2) | FGL |
Research summary only — not medical advice. Consult a qualified provider before making any decisions.
Davunetide
FGL
Davunetide
Microtubule-stabilizing drugs suppress convulsions in a C. elegans model of CAMSAP disorders.
Effects of davunetide on N-acetylaspartate and choline in dorsolateral prefrontal cortex in patients with sch…
Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophren…
FGL
No citations on file.
About Davunetide
Stabilizes microtubules by interacting with tubulin and microtubule-associated proteins. Activates SIRT1, reduces amyloid-β toxicity, and enhances synaptic plasticity. Protects against tau hyperphosphorylation.
About FGL
Mimics NCAM-mediated signaling via FGFR (fibroblast growth factor receptor) activation. Stimulates downstream Erk1/2 and PLCγ pathways. Promotes long-term potentiation (LTP) and synaptogenesis.
Information below reflects published research data only — not medical advice. Consult a qualified provider before use.
Davunetide
No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.
FGL
No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.
Where to source these peptides
PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.
More Neuro & Cognitive Comparisons
Browse all peptides →Educational research tools — not medical advice.